Provided by Tiger Trade Technology Pte. Ltd.

Allarity Therapeutics Inc

1.02
-0.0300-2.86%
Volume:108.40K
Turnover:110.13K
Market Cap:16.40M
PE:-0.76
High:1.06
Open:1.05
Low:0.9830
Close:1.05
52wk High:2.35
52wk Low:0.6138
Shares:16.08M
Float Shares:16.06M
Volume Ratio:1.03
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3348
EPS(LYR):-15.6529
ROE:-122.61%
ROA:-51.62%
PB:1.37
PE(LYR):-0.07

Loading ...

Allarity Therapeutics Announces Landmark Phase 2 Results: Stenoparib Surpasses 25-Month Median Overall Survival in Advanced Ovarian Cancer Trial

Reuters
·
Sep 24, 2025

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025 Conference

Reuters
·
Sep 23, 2025

Allarity presents new Phase 2 clinical data for Stenoparib

TIPRANKS
·
Sep 22, 2025

Allarity Therapeutics Inc: Median Overall Survival Exceeds 25 Months for Ovarian Cancer Patients Receiving Stenoparib/2X-121 Twice Daily

THOMSON REUTERS
·
Sep 22, 2025

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

GlobeNewswire
·
Sep 22, 2025

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

GlobeNewswire
·
Sep 17, 2025

Sector Update: Health Care Stocks Rise Tuesday Afternoon

MT Newswires Live
·
Aug 27, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Trump Media, Gold miners, Cracker Barrel

Reuters
·
Aug 26, 2025

BUZZ-Allarity more than doubles on US FDA's 'fast track' tag for ovarian cancer therapy

Reuters
·
Aug 26, 2025

Allarity Therapeutics Shares Surge 125% on FDA's Fast Track Tag for Ovarian Cancer Therapy

THOMSON REUTERS
·
Aug 26, 2025

Allarity Therapeutics Shares Jump 80% Premarket on FDA's Fast Track Tag for Ovarian Cancer Therapy

THOMSON REUTERS
·
Aug 26, 2025

Allarity Therapeutics Says FDA Granted Fast-Track Designation to Stenoparib; Shares Rise Pre-Bell

MT Newswires Live
·
Aug 26, 2025

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

THOMSON REUTERS
·
Aug 26, 2025